Anavex Life Sciences Corp (AVXL)

[Investor2014]

That chart is on slide 18 of the Feb 2024 Corp presentation and same in JPM Jan 2024 deck - I'm sure you couldn't have missed it.



Note that the chart is not showing data from Anavex, but from the ADNI | ACCESS DATA imagining reference dataset.

So the chart represents a general indication that there is correspondence between Plasma Aß42/40 (as measured in the P2b/3 trial) and the standard accepted PET scan for amyloid status used in other AD trials. Per the paper referenced by Anavex in footnote 2 Validation of Plasma Amyloid-ß 42/40 for Detecting Alzheimer Disease Amyloid Plaques, there is good concordance with amyloid PET status. However, Plasma Aß42/40 has not been accepted by regulators yet in place of amyloid PET status but of course it is helpful.

We have to my knowledge not yet seen the Anavex data on Plasma Aß42/40, but sounds like it will be part of the peer reviewed P2b/3 data publication.

Since everyone loves to ask AI these days, here we go:

User
Has Plasma Aß42/40 alone predicted amyloid PET status in
Alzheimer’s disease clinical trials?
ChatGPT
As of my last knowledge update in January 2022, I don't have specific information on individual clinical trials or the latest developments in Alzheimer's disease research after that date. Predicting amyloid PET status in Alzheimer's disease using plasma biomarkers, such as the ratio of plasma Aß42/40, has been a topic of interest in the field.

Plasma biomarkers, including Aß42/40 ratios, have been investigated as potential non-invasive tools for predicting amyloid deposition in the brain, which is a hallmark of Alzheimer's disease. However, the use of plasma biomarkers alone for predicting amyloid PET status has been a subject of ongoing research and validation.

To get the most recent and accurate information on this topic, I recommend checking the latest literature, research articles, and updates from reputable sources in Alzheimer's disease research. Clinical trial databases, such as ClinicalTrials.gov, may also provide insights into ongoing trials and their findings related to the use of plasma biomarkers in Alzheimer's disease diagnosis and prediction.